<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32928939</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-330X</ISSN><JournalIssue CitedMedium="Internet"><Volume>91</Volume><Issue>12</Issue><PubDate><Year>2020</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of neurology, neurosurgery, and psychiatry</Title><ISOAbbreviation>J Neurol Neurosurg Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Untargeted metabolomics yields insight into ALS disease mechanisms.</ArticleTitle><Pagination><StartPage>1329</StartPage><EndPage>1338</EndPage><MedlinePgn>1329-1338</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/jnnp-2020-323611</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To identify dysregulated metabolic pathways in amyotrophic lateral sclerosis (ALS) versus control participants through untargeted metabolomics.</AbstractText><AbstractText Label="METHODS">Untargeted metabolomics was performed on plasma from ALS participants (n=125) around 6.8 months after diagnosis and healthy controls (n=71). Individual differential metabolites in ALS cases versus controls were assessed by Wilcoxon rank-sum tests, adjusted logistic regression and partial least squares-discriminant analysis (PLS-DA), while group lasso explored sub-pathway-level differences. Adjustment parameters included sex, age and body mass index (BMI). Metabolomics pathway enrichment analysis was performed on metabolites selected by the above methods. Finally, machine learning classification algorithms applied to group lasso-selected metabolites were evaluated for classifying case status.</AbstractText><AbstractText Label="RESULTS">There were no group differences in sex, age and BMI. Significant metabolites selected were 303 by Wilcoxon, 300 by logistic regression, 295 by PLS-DA and 259 by group lasso, corresponding to 11, 13, 12 and 22 enriched sub-pathways, respectively. 'Benzoate metabolism', 'ceramides', 'creatine metabolism', 'fatty acid metabolism (acyl carnitine, polyunsaturated)' and 'hexosylceramides' sub-pathways were enriched by all methods, and 'sphingomyelins' by all but Wilcoxon, indicating these pathways significantly associate with ALS. Finally, machine learning prediction of ALS cases using group lasso-selected metabolites achieved the best performance by regularised logistic regression with elastic net regularisation, with an area under the curve of 0.98 and specificity of 83%.</AbstractText><AbstractText Label="CONCLUSION">In our analysis, ALS led to significant metabolic pathway alterations, which had correlations to known ALS pathomechanisms in the basic and clinical literature, and may represent important targets for future ALS therapeutics.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goutman</LastName><ForeName>Stephen A</ForeName><Initials>SA</Initials><Identifier Source="ORCID">0000-0001-8780-6637</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boss</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Kai</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of North Dakota, Grand Forks, North Dakota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alakwaa</LastName><ForeName>Fadhl M</ForeName><Initials>FM</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patterson</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Sehee</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savelieff</LastName><ForeName>Masha Georges</ForeName><Initials>MG</Initials><Identifier Source="ORCID">0000-0001-5575-2494</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hur</LastName><ForeName>Junguk</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of North Dakota, Grand Forks, North Dakota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feldman</LastName><ForeName>Eva L</ForeName><Initials>EL</Initials><Identifier Source="ORCID">0000-0002-9162-2694</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, Michigan, USA efeldman@umich.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 ES027221</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 ES030049</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 TS000289</GrantID><Acronym>TS</Acronym><Agency>ATSDR CDC HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurol Neurosurg Psychiatry</MedlineTA><NlmUniqueID>2985191R</NlmUniqueID><ISSNLinking>0022-3050</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001565">Benzoates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002518">Ceramides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005227">Fatty Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005231">Fatty Acids, Unsaturated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C116917">acylcarnitine</NameOfSubstance></Chemical><Chemical><RegistryNumber>MU72812GK0</RegistryNumber><NameOfSubstance UI="D003401">Creatine</NameOfSubstance></Chemical><Chemical><RegistryNumber>S7UI8SM58A</RegistryNumber><NameOfSubstance UI="D002331">Carnitine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Neurol Neurosurg Psychiatry. 2020 Dec;91(12):1250</RefSource><PMID Version="1">32928936</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001565" MajorTopicYN="N">Benzoates</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002331" MajorTopicYN="N">Carnitine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002518" MajorTopicYN="N">Ceramides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003401" MajorTopicYN="N">Creatine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016002" MajorTopicYN="N">Discriminant Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005227" MajorTopicYN="N">Fatty Acids</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005231" MajorTopicYN="N">Fatty Acids, Unsaturated</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016018" MajorTopicYN="N">Least-Squares Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069550" MajorTopicYN="N">Machine Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053858" MajorTopicYN="N">Metabolic Networks and Pathways</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055432" MajorTopicYN="Y">Metabolomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests: SAG has provided medical advisory for Biogen and ITF Pharma and served on a DSMB. JB, KG, FMA, AP, SK, MGS and JH report no disclosures relevant to the manuscript. EF sits on an advisory board for Novartis.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>4</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>15</Day><Hour>5</Hour><Minute>41</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32928939</ArticleId><ArticleId IdType="pmc">PMC7677469</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2020-323611</ArticleId><ArticleId IdType="pii">jnnp-2020-323611</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goutman SA. Diagnosis and clinical management of amyotrophic lateral sclerosis and other motor neuron disorders. Continuum 2017;23:1332&#x2013;59. 10.1212/CON.0000000000000535</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/CON.0000000000000535</ArticleId><ArticleId IdType="pubmed">28968365</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman SA, Chen KS, Paez-Colasante X, et al. . Emerging understanding of the genotype-phenotype relationship in amyotrophic lateral sclerosis. Handb Clin Neurol 2018;148:603&#x2013;23. 10.1016/B978-0-444-64076-5.00039-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-444-64076-5.00039-9</ArticleId><ArticleId IdType="pubmed">29478603</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia R, Chi&#xf2; A, Traynor BJ. Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. Lancet Neurol 2018;17:94&#x2013;102. 10.1016/S1474-4422(17)30401-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30401-5</ArticleId><ArticleId IdType="pmc">PMC5901717</ArticleId><ArticleId IdType="pubmed">29154141</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman SA, Boss J, Patterson A, et al. . High plasma concentrations of organic pollutants negatively impact survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2019;90:907&#x2013;12. 10.1136/jnnp-2018-319785</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-319785</ArticleId><ArticleId IdType="pmc">PMC6625908</ArticleId><ArticleId IdType="pubmed">30760645</ArticleId></ArticleIdList></Reference><Reference><Citation>Su F-C, Goutman SA, Chernyak S, et al. . Association of environmental toxins with amyotrophic lateral sclerosis. JAMA Neurol 2016;73:803&#x2013;11. 10.1001/jamaneurol.2016.0594</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2016.0594</ArticleId><ArticleId IdType="pmc">PMC5032145</ArticleId><ArticleId IdType="pubmed">27159543</ArticleId></ArticleIdList></Reference><Reference><Citation>Patin F, Corcia P, Vourc'h P, et al. . Omics to explore amyotrophic lateral sclerosis evolution: the central role of arginine and proline metabolism. Mol Neurobiol 2017;54:5361&#x2013;74. 10.1007/s12035-016-0078-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-016-0078-x</ArticleId><ArticleId IdType="pubmed">27590138</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasco H, Corcia P, Moreau C, et al. . 1H-NMR-based metabolomic profiling of CSF in early amyotrophic lateral sclerosis. PLoS One 2010;5:e13223. 10.1371/journal.pone.0013223</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0013223</ArticleId><ArticleId IdType="pmc">PMC2951909</ArticleId><ArticleId IdType="pubmed">20949041</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasco H, Veyrat-Durebex C, Bocca C, et al. . Lipidomics reveals cerebrospinal-fluid signatures of ALS. Sci Rep 2017;7:17652. 10.1038/s41598-017-17389-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-17389-9</ArticleId><ArticleId IdType="pmc">PMC5732162</ArticleId><ArticleId IdType="pubmed">29247199</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol 2013;9:617&#x2013;28. 10.1038/nrneurol.2013.203</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2013.203</ArticleId><ArticleId IdType="pubmed">24126629</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshino H, Kimura A. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (phase II study). Amyotroph Lateral Scler 2006;7:241&#x2013;5. 10.1080/17482960600881870</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960600881870</ArticleId><ArticleId IdType="pubmed">17127563</ArticleId></ArticleIdList></Reference><Reference><Citation>Athersuch T. Metabolome analyses in exposome studies: profiling methods for a vast chemical space. Arch Biochem Biophys 2016;589:177&#x2013;86. 10.1016/j.abb.2015.10.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.abb.2015.10.007</ArticleId><ArticleId IdType="pubmed">26494045</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasco H, Patin F, Madji Hounoum B, et al. . Metabolomics in amyotrophic lateral sclerosis: how far can it take us? Eur J Neurol 2016;23:447&#x2013;54. 10.1111/ene.12956</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12956</ArticleId><ArticleId IdType="pubmed">26822316</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozen S, Cudkowicz ME, Bogdanov M, et al. . Metabolomic analysis and signatures in motor neuron disease. Metabolomics 2005;1:101&#x2013;8. 10.1007/s11306-005-4810-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11306-005-4810-1</ArticleId><ArticleId IdType="pmc">PMC2553219</ArticleId><ArticleId IdType="pubmed">18820733</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjornevik K, Zhang Z, O'Reilly &#xc9;ilis J, et al. . Prediagnostic plasma metabolomics and the risk of amyotrophic lateral sclerosis. Neurology 2019;92:e2089&#x2013;100. 10.1212/WNL.0000000000007401</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000007401</ArticleId><ArticleId IdType="pmc">PMC6512888</ArticleId><ArticleId IdType="pubmed">30926684</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawton KA, Brown MV, Alexander D, et al. . Plasma metabolomic biomarker panel to distinguish patients with amyotrophic lateral sclerosis from disease mimics. Amyotroph Lateral Scler Frontotemporal Degener 2014;15:362&#x2013;70. 10.3109/21678421.2014.908311</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.908311</ArticleId><ArticleId IdType="pubmed">24984169</ArticleId></ArticleIdList></Reference><Reference><Citation>Dehaven CD, Evans AM, Dai H, et al. . Organization of GC/MS and LC/MS metabolomics data into chemical libraries. J Cheminform 2010;2:9. 10.1186/1758-2946-2-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1758-2946-2-9</ArticleId><ArticleId IdType="pmc">PMC2984397</ArticleId><ArticleId IdType="pubmed">20955607</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans A, Bridgewater B, Liu Q, et al. . High resolution mass spectrometry improves data quantity and quality as compared to unit mass resolution mass spectrometry in high-throughput profiling metabolomics. Metabolomics 2014;4.</Citation></Reference><Reference><Citation>Rohart F, Gautier B, Singh A, et al. . mixOmics: An R package for 'omics feature selection and multiple data integration. PLoS Comput Biol 2017;13:e1005752. 10.1371/journal.pcbi.1005752</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1005752</ArticleId><ArticleId IdType="pmc">PMC5687754</ArticleId><ArticleId IdType="pubmed">29099853</ArticleId></ArticleIdList></Reference><Reference><Citation>Galindo-Prieto B, Eriksson L, Trygg J. Variable influence on projection (VIP) for orthogonal projections to latent structures (OPLS). J Chemom 2014;28:623&#x2013;32. 10.1002/cem.2627</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cem.2627</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho H-W, Kim SB, Jeong MK, et al. . Discovery of metabolite features for the modelling and analysis of high-resolution NMR spectra. Int J Data Min Bioinform 2008;2:176&#x2013;92. 10.1504/ijdmb.2008.019097</Citation><ArticleIdList><ArticleId IdType="doi">10.1504/ijdmb.2008.019097</ArticleId><ArticleId IdType="pmc">PMC3883573</ArticleId><ArticleId IdType="pubmed">18767354</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn M. Building predictive models in R using the CARET package 2008;28:26.</Citation></Reference><Reference><Citation>Chawla NV, Bowyer KW, Hall LO, et al. . SMOTE: synthetic minority over-sampling technique. J Artif Int Res 2002;16:321&#x2013;57.</Citation></Reference><Reference><Citation>Robin X, Turck N, Hainard A, et al. . pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 2011;12:77. 10.1186/1471-2105-12-77</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-12-77</ArticleId><ArticleId IdType="pmc">PMC3068975</ArticleId><ArticleId IdType="pubmed">21414208</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandres-Ciga S, Noyce AJ, Hemani G, et al. . Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. Ann Neurol 2019;85:470&#x2013;81. 10.1002/ana.25431</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25431</ArticleId><ArticleId IdType="pmc">PMC6450729</ArticleId><ArticleId IdType="pubmed">30723964</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawton KA, Cudkowicz ME, Brown MV, et al. . Biochemical alterations associated with ALS. Amyotroph Lateral Scler 2012;13:110&#x2013;8. 10.3109/17482968.2011.619197</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2011.619197</ArticleId><ArticleId IdType="pubmed">22117131</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito D, Hashizume A, Hijikata Y, et al. . Elevated serum creatine kinase in the early stage of sporadic amyotrophic lateral sclerosis. J Neurol 2019;266:2952&#x2013;61. 10.1007/s00415-019-09507-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-019-09507-6</ArticleId><ArticleId IdType="pubmed">31456060</ArticleId></ArticleIdList></Reference><Reference><Citation>Wuolikainen A, Jonsson P, Ahnlund M, et al. . Multi-platform mass spectrometry analysis of the CSF and plasma metabolomes of rigorously matched amyotrophic lateral sclerosis, Parkinson's disease and control subjects. Mol Biosyst 2016;12:1287&#x2013;98. 10.1039/c5mb00711a</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/c5mb00711a</ArticleId><ArticleId IdType="pubmed">26883206</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A, Bala L, Kalita J, et al. . Metabolomic analysis of serum by (1) H NMR spectroscopy in amyotrophic lateral sclerosis. Clinica Chimica Acta 2010;411:563&#x2013;7. 10.1016/j.cca.2010.01.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2010.01.016</ArticleId><ArticleId IdType="pubmed">20096678</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner JM, Cudkowicz ME, Schoenfeld D, et al. . A clinical trial of creatine in ALS. Neurology 2004;63:1656&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">15534251</ArticleId></ArticleIdList></Reference><Reference><Citation>Hannun YA, Obeid LM. Sphingolipids and their metabolism in physiology and disease. Nat Rev Mol Cell Biol 2018;19:175&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5902181</ArticleId><ArticleId IdType="pubmed">29165427</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang ML, Chiang S, Kalinowski DS, et al. . The role of the antioxidant response in mitochondrial dysfunction in degenerative diseases: cross-talk between antioxidant defense, autophagy, and apoptosis. Oxid Med Cell Longev 2019;2019:6392763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6476015</ArticleId><ArticleId IdType="pubmed">31057691</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutler RG, Pedersen WA, Camandola S, et al. . Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis. Ann Neurol 2002;52:448&#x2013;57. 10.1002/ana.10312</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.10312</ArticleId><ArticleId IdType="pubmed">12325074</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodge JC, Treleaven CM, Pacheco J, et al. . Glycosphingolipids are modulators of disease pathogenesis in amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 2015;112:8100&#x2013;5. 10.1073/pnas.1508767112</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1508767112</ArticleId><ArticleId IdType="pmc">PMC4491749</ArticleId><ArticleId IdType="pubmed">26056266</ArticleId></ArticleIdList></Reference><Reference><Citation>Henriques A, Croixmarie V, Bouscary A, et al. . Sphingolipid metabolism is dysregulated at transcriptomic and metabolic levels in the spinal cord of an animal model of amyotrophic lateral sclerosis. Front Mol Neurosci 2017;10:433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5758557</ArticleId><ArticleId IdType="pubmed">29354030</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaves-Filho AB, Pinto IFD, Dantas LS, et al. . Alterations in lipid metabolism of spinal cord linked to amyotrophic lateral sclerosis. Sci Rep 2019;9:11642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6691112</ArticleId><ArticleId IdType="pubmed">31406145</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw J, Costa-Pinheiro P, Patterson L, et al. . Novel sphingolipid-based cancer therapeutics in the personalized medicine era. Adv Cancer Res 2018;140:327&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6320700</ArticleId><ArticleId IdType="pubmed">30060815</ArticleId></ArticleIdList></Reference><Reference><Citation>Angelopoulou E, Piperi C. Beneficial effects of fingolimod in Alzheimer's disease: molecular mechanisms and therapeutic potential. Neuromolecular Med 2019;21:227&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">31313064</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Pardo A, Maglione V. Sphingolipid metabolism: a new therapeutic opportunity for brain degenerative disorders. Front Neurosci 2018;12:249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5913346</ArticleId><ArticleId IdType="pubmed">29719499</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasco H, Nadal-Desbarats L, Pradat P-F, et al. . Biomarkers in amyotrophic lateral sclerosis: combining metabolomic and clinical parameters to define disease progression. Eur J Neurol 2016;23:346&#x2013;53. 10.1111/ene.12851</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12851</ArticleId><ArticleId IdType="pubmed">26508442</ArticleId></ArticleIdList></Reference><Reference><Citation>Madeo F, Eisenberg T, Pietrocola F, et al. . Spermidine in health and disease. Science 2018;359.</Citation><ArticleIdList><ArticleId IdType="pubmed">29371440</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock BJ, Bender DE, Segal BM, et al. . The dual roles of immunity in ALS: injury overrides protection. Neurobiol Dis 2015;77:1&#x2013;12. 10.1016/j.nbd.2015.02.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2015.02.017</ArticleId><ArticleId IdType="pubmed">25726748</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang IF, Guo BS, Liu YC, et al. . Autophagy activators rescue and alleviate pathogenesis of a mouse model with proteinopathies of the TAR DNA-binding protein 43. Proc Natl Acad Sci U S A 2012;109:15024&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3443184</ArticleId><ArticleId IdType="pubmed">22932872</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J, Ryu H, Kowall NW. Motor neuronal protection by L-arginine prolongs survival of mutant SOD1 (G93A) ALS mice. Biochem Biophys Res Commun 2009;384:524&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2744197</ArticleId><ArticleId IdType="pubmed">19427829</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirth M, Schwarz C, Benson G, et al. . Effects of spermidine supplementation on cognition and biomarkers in older adults with subjective cognitive decline (SmartAge)-study protocol for a randomized controlled trial. Alzheimers Res Ther 2019;11:36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6492385</ArticleId><ArticleId IdType="pubmed">31039826</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Amico E, Factor-Litvak P, Santella RM, et al. . Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis. Free Radic Biol Med 2013;65:509&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3859834</ArticleId><ArticleId IdType="pubmed">23797033</ArticleId></ArticleIdList></Reference><Reference><Citation>Forman HJ, Zhang H, Rinna A. Glutathione: overview of its protective roles, measurement, and biosynthesis. Mol Aspects Med 2009;30:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696075</ArticleId><ArticleId IdType="pubmed">18796312</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiduschat N, Mao X, Hupf J, et al. . Motor cortex glutathione deficit in ALS measured in vivo with the J-editing technique. Neurosci Lett 2014;570:102&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">24769125</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Alessandro G, Calcagno E, Tartari S, et al. . Glutamate and glutathione interplay in a motor neuronal model of amyotrophic lateral sclerosis reveals altered energy metabolism. Neurobiol Dis 2011;43:346&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">21530659</ArticleId></ArticleIdList></Reference><Reference><Citation>Veyrat-Durebex C, Corcia P, Piver E, et al. . Disruption of TCA cycle and glutamate metabolism identified by metabolomics in an in vitro model of amyotrophic lateral sclerosis. Mol Neurobiol 2016;53:6910&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">26666663</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L, Lv X, Du H, et al. . Causal effects of serum metabolites on amyotrophic lateral sclerosis: a Mendelian randomization study. Prog Neuropsychopharmacol Biol Psychiatry 2020;97:109771.</Citation><ArticleIdList><ArticleId IdType="pubmed">31669200</ArticleId></ArticleIdList></Reference><Reference><Citation>Desnuelle C, Dib M, Garrel C, et al. . A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group. Amyotroph Lateral Scler Other Motor Neuron Disord 2001;2:9&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">11465936</ArticleId></ArticleIdList></Reference><Reference><Citation>Dardiotis E, Siokas V, Sokratous M, et al. . Body mass index and survival from amyotrophic lateral sclerosis: a meta-analysis. Neurol Clin Pract 2018;8:437&#x2013;44. 10.1212/CPJ.0000000000000521</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/CPJ.0000000000000521</ArticleId><ArticleId IdType="pmc">PMC6276330</ArticleId><ArticleId IdType="pubmed">30564498</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Wang T, YJ J, et al. . A C9orf72-CARM1 axis regulates lipid metabolism under glucose starvation-induced nutrient stress. Genes Dev 2018;32:1380&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6217731</ArticleId><ArticleId IdType="pubmed">30366907</ArticleId></ArticleIdList></Reference><Reference><Citation>Toker A. The biology and biochemistry of diacylglycerol signalling. Meeting on molecular advances in diacylglycerol signalling. EMBO Rep 2005;6:310&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1299288</ArticleId><ArticleId IdType="pubmed">15791268</ArticleId></ArticleIdList></Reference><Reference><Citation>Purow B. Molecular pathways: targeting diacylglycerol kinase alpha in cancer. Clin Cancer Res 2015;21:5008&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4644682</ArticleId><ArticleId IdType="pubmed">26420856</ArticleId></ArticleIdList></Reference><Reference><Citation>Cereda C, Gabanti E, Corato M, et al. . Increased incidence of FMO1 gene single nucleotide polymorphisms in sporadic amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2006;7:227&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">17127561</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>